(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 91.5MM | +23% |
Gross Profit | 7MM | - |
Cost Of Revenue | 84.6MM | - |
Operating Income | -68.9MM | - |
Operating Expenses | 75.9MM | - |
Net Income | -79.7MM | - |
R&D | 26.4MM | +3% |
G&A | 49.5MM | +3% |
Amortization | - | - |
Interest Expense | 10.6MM | +3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
With the business potentially at an important milestone, we thought we'd take a closer look at Coherus BioSciences...
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-res
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion o
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy –– First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 – REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript March 13, 2024 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.21. CHRS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
Coherus BioSciences ( NASDAQ:CHRS ) Full Year 2023 Results Key Financial Results Revenue: US$257.2m (up 22% from FY...
The company fell well short of expectations for its fourth quarter.
Q4 2023 Coherus BioSciences Inc Earnings Call